# Phibro Animal Health Corp: Form 10-Q for the period ended Mar 31, 2025

- Company: [Phibro Animal Health Corp](/companies/pahc.md) (CIK 1069899)
- Form: 10-Q
- Filed: 2025-05-07
- Accepted by EDGAR: May 7, 2025, 16:16 ET
- Period: 2025-03-31
- Accession: 0001558370-25-006746
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1069899/000155837025006746/pahc-20250331x10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1069899/000155837025006746/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2025-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2025-01-01 to 2025-03-31 | $347.8m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months, 2024-07-01 to 2025-03-31 | $917.5m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2025-01-01 to 2025-03-31 | $243.3m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2024-07-01 to 2025-03-31 | $627.6m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2025-01-01 to 2025-03-31 | $104.6m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2024-07-01 to 2025-03-31 | $289.9m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months, 2025-01-01 to 2025-03-31 | $71.1m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2024-07-01 to 2025-03-31 | $213.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2025-01-01 to 2025-03-31 | $33.5m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2024-07-01 to 2025-03-31 | $76.7m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2025-01-01 to 2025-03-31 | $9.7m | us-gaap:InterestExpenseNonoperating |
| Interest expense | 9 months, 2024-07-01 to 2025-03-31 | $28.2m | us-gaap:InterestExpenseNonoperating |
| Income tax | 3 months, 2025-01-01 to 2025-03-31 | $8.8m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2024-07-01 to 2025-03-31 | $13.1m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2025-01-01 to 2025-03-31 | $20.9m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2024-07-01 to 2025-03-31 | $31.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2025-01-01 to 2025-03-31 | $0.51 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2024-07-01 to 2025-03-31 | $0.76 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2025-01-01 to 2025-03-31 | $0.52 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2024-07-01 to 2025-03-31 | $0.77 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2025-01-01 to 2025-03-31 | 40,709,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2024-07-01 to 2025-03-31 | 40,669,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2024-07-01 to 2025-03-31 | $58.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2024-07-01 to 2025-03-31 | $25.2m | us-gaap:PaymentsToAcquireProductiveAssets |
| Dividends paid | 9 months, 2024-07-01 to 2025-03-31 | $14.6m | us-gaap:PaymentsOfDividendsCommonStock |
| Cash and equivalents | at 2025-03-31 | $60.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2025-03-31 | $776.0m | us-gaap:AssetsCurrent |
| Total assets | at 2025-03-31 | $1.32bn | us-gaap:Assets |
| Current liabilities | at 2025-03-31 | $266.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2025-03-31 | $1.05bn | us-gaap:Liabilities |
| Long-term debt | at 2025-03-31 | $619.2m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2025-03-31 | $16.3m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2025-03-31 | $266.0m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 64,648 characters.

### Introduction

Our management’s discussion and analysis of financial condition and results of operations (“MD&A”) is provided to assist readers in understanding our performance, as reflected in the results of our operations, our financial condition and our cash flows. The following discussion summarizes the significant factors affecting our consolidated operating results, financial condition, liquidity and cash flows as of and for the periods presented below. This MD&A should be read in conjunction with our consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report on Form 10-Q. Our future results could differ materially from our historical performance as a result of various factors such as those discussed in “Risk Factors” in Item 1A of our Annual Report and “Forward-Looking Statements.”

### Overview of our business

Phibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company. We develop, manufacture and market a broad range of products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. Our products help prevent, control and treat diseases, and support nutrition to help improve animal health and well-being. In addition to animal health and mineral nutrition products, we manufacture and market specific ingredients for use in the personal care, industrial chemical and chemical catalyst industries.

### Acquisition

In April 2024, the Company entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with Zoetis Inc., a Delaware corporation (“Zoetis”) to acquire Zoetis’s medicated feed additive (“MFA”) portfolio, certain water-soluble products and related assets (the “Acquisition”). On October 31, 2024, the Company completed the Acquisition at a purchase price of approximately $302.9 million ($291.9 million, as adjusted, net of cash acquired), subject to certain further adjustments set forth in the Purchase Agreement. The Acquisition was funded by term loan borrowings under the 2024 Credit Agreement. The product portfolio acquired, which generated $407.6 million in revenue in 2023, is comprised of more than 37 product lines that are sold in approximately 80 countries. Also included in the Acquisition are six manufacturing sites, comprised of four in the U.S., one in Italy and one in China. The results of operations of the Acquisition are included in our consolidated statements of operations from the date of acquisition and reported within the Animal Health segment.

### 2024 Credit Agreement

In July 2024, we entered into a Credit Agreement (the “2024 Credit Agreement”) with a group of lenders. Initial borrowings were used to refinance all our outstanding debt, to pay fees and expenses of the transaction, and for ongoing working capital requirements and general corporate purposes. Borrowings under the Delayed Draw Term A-1 and A-2 Loans were used to finance the purchase price of the Acquisition. See “Notes to Consolidated Financial Statements — Debt — 2024 Credit Agreement” for additional information.

### Armed Conflicts

#### Israel and Hamas

On October 7, 2023, Hamas militants crossed into Israel from Gaza in a large-scale, surprise terrorist attack. Hamas terrorists invaded Israel, first firing rockets into the country and then carrying out attacks inflicting mass casualties with hundreds more taken hostage. In order to provide immediate assistance to the victims of the attacks and their families, we and our employees provided monetary donations that were distributed to charities that offered relief services, welfare, equipment, food and other necessities. Since the October 2023 attack, there have been continued and escalating hostilities along Israel’s northern border with Lebanon (with the Hezbollah terror organization) and southern border (with the Houthi movement in Yemen). Although a ceasefire was brokered between Israel and Hezbollah in November 2024, and in January 2025, a temporary ceasefire went into effect between Israel and Hamas, hostilities in the region have recently resumed. The possibility of negotiations for renewed ceasefire agreements between Israel and Hamas and Israel and Hezbollah remain uncertain and difficult to predict and until resolved, may continue to cause conflict in the region.

We have three manufacturing sites in Israel. A manufacturing plant in Neot Hovav that produces active pharmaceutical ingredients for certain of our anticoccidial and antimicrobial products, a facility in Beit Shemesh that produces vaccines and a plant in Petah Tikvah that manufactures premix products and nutritional products. In addition, we have an office location near Tel Aviv in Airport City. As of March 31, 2025, we had approximately 500 employees located in Israel. While we initially had some disruption to our operations at the onset of the Israel-Hamas conflict, at the current time, we have confidence in our ability to meet our supply commitment to customers and maintain sufficient inventory to continue regional support. A significant escalation of the tensions in Israel occurred on April 13, 2024, when Iran launched more than 300 drones and missiles against Israel, but we had no material disruption to our business. Iran has threatened to continue to attack Israel. Iran is also believed to have a strong influence among extremist groups in the region, such as Hamas in Gaza, Hezbollah in Lebanon, the Houthi movement in Yemen and various rebel militia groups in Syria and Iraq. While the situation surrounding the ongoing conflict remains fluid, our operations in Israel have navigated numerous challenging situations over the years.

The resumption, prolonged continuation or escalation of this conflict may trigger bans, economic and other sanctions, as well as broader military conflict, which could include neighboring nations and their respective allies. The potential impact of the current conflict, or escalation thereof, on our business is unclear but may include, without limitation, the possible disruption of our operations, particularly at our facilities in Israel, supply chain and logistics disruptions, personnel and raw material shortages, and other consequences, including as a result of the actions of, or disruption of the operations of, certain regulatory and governmental authorities and of certain of our suppliers, collaborative partners, licensees, manufacturing sites, distributors and customers. Our Israeli manufacturing facilities and local operations account for 16% of our consolidated assets as of March 31, 2025, and 19% of our consolidated net sales for the nine months ended March 31, 2025.

#### Russia and Ukraine

In response to the armed conflict between Russia and Ukraine that began in February 2022, we and our employees have provided support to Ukraine in the form of monetary donations, free products and humanitarian services. Our limited intent for the Russian market is to continue to provide medicines and vaccines, and related regulatory and technical support, to help existing customers combat disease challenges in the production of food animals on their farms. We have no production or direct distribution operations and no planned investments in Russia.

Since the conflict began, the United States and other North Atlantic Treaty Organization (“NATO”) member states, as well as non-member states, announced targeted economic sanctions on Russia, including certain Russian citizens and enterprises. The continuation or escalation of the conflict may trigger additional economic and other sanctions, as well as broader military conflict. The potential impacts of any resulting bans, sanctions, boycotts or broader military conflicts on our business are uncertain. The potential impacts could include supply chain and logistics disruptions, macroeconomic impacts resulting from the exclusion of Russian financial institutions from the global banking system, volatility in foreign exchange rates and interest rates, inflationary pressures on raw materials and energy as well as heightened cybersecurity threats. Our sales to Russia and Ukraine for the twelve months ended March 31, 2025 represented approximately 1% of consolidated net sales.

We cannot know if the conflict could escalate and result in broader economic and security concerns that could adversely affect our business, financial condition, or results of operations.

### Industry growth

We believe global population growth, the growth of the global middle class and the productivity improvements needed due to limitations of arable land and water supplies have supported and will continue to support growth of the animal health industry.

### Regulatory developments

In April 2016, the Food and Drug Administration (“FDA”) began initial steps to withdraw approval of carbadox (the active ingredient in our Mecadox product) via a regulatory process known as a Notice of Opportunity for Hearing (“NOOH”), due to concerns that certain residues from the product may persist in animal tissues for longer than previously determined. In the years following, Phibro has continued an ongoing process of responding collaboratively and transparently to the FDA’s Center for Veterinary Medicine (“CVM”) inquiries and has provided extensive and meticulous research and data that confirmed the safety of carbadox. In July 2020, the FDA announced it would not proceed to a hearing on the scientific concerns raised in the 2016 NOOH, consistent with the normal regulatory procedure, but instead announced that it was withdrawing the 2016 NOOH and issuing a proposed order to review the regulatory method for carbadox. Phibro reiterated the safety of carbadox and the appropriateness of the regulatory method and offered to work with the CVM to generate additional data to support the existing regulatory method or select a suitable alternative regulatory method.

In March 2022, the FDA held a Part 15 virtual public hearing seeking data and information related to the safety of carbadox in which Phibro participated and again detailed the research and data that confirm the safety of carbadox. In November 2023, the FDA issued a final order to revoke the approved method for detecting carbadox residues. The FDA also provided notice in the Federal Register proposing to withdraw approval of all NADAs providing for use of carbadox in medicated swine feed and announcing an opportunity for Phibro to request a hearing on this proposal. This second action is based on CVM’s determination that there is no approved regulatory method to detect carbadox residues in the edible tissues of the treated swine. Phibro is continuing to defend swine producers’ ability to use Mecadox. We have requested a full evidentiary hearing on the merits before an administrative law judge. In January 2024, Phibro filed a lawsuit in the D.C. Federal District Court asking the court to invalidate the order which revoked the regulatory method for carbadox. Should we be unable to successfully defend the safety of the product, the loss of carbadox sales will have an adverse effect on our financial condition and results of operations. Sales of Mecadox (carbadox) for the twelve months ended March 31, 2025 were approximately $22 million. As of the date of the filing of this Quarterly Report on Form 10-Q, Mecadox continues to be available for use by swine producers.

Macroeconomic developments, such as adverse economic conditions worldwide, international conflicts, or efforts of governments to stimulate or stabilize the economy or manage trade disputes, may adversely impact our business. For example, the Trump administration recently instituted or proposed changes in trade policies that include the renegotiation or termination of existing trade agreements, the imposition of higher tariffs on imports into the United States, and other government regulations affecting trade between the United States and other countries. These measures aim to address broader policy goals but could introduce supply chain inefficiencies, challenge current trade agreements with certain nations, and affect the cost and availability of materials critical to project execution. Any such tariffs, if and when enacted, and any further legislation or actions taken by the U.S. federal government that restrict trade, such as additional tariffs, trade barriers, and other protectionist or retaliatory measures could adversely impact our ability to sell products and services in our markets. Countries may, in response to any U.S. actions, adopt retaliatory or other protectionist measures that could further limit our ability to offer our products and services. The ultimate impact of any tariffs will depend on various factors, including if any tariffs are ultimately implemented, the timing of implementation, and the amount, scope, and nature of the tariffs.

### Analysis of the consolidated statements of operations

### Summary Results of Operations

*(in thousands, except per share amounts and percentages)*

| ​ ​ For the Periods Ended March 31 ​ | ​ ​ ​ | ​ ​ ​ Three Months 2025 | ​ ​ ​ 2024 | ​ ​ Change | ​ | ​ ​ ​ | ​ ​ | ​ ​ ​ Nine Months 2025 | ​ ​ ​ 2024 | ​ ​ Change | ​ | ​ ​ ​ ​ ​ |
| --- | --- | ---: | ---: | ---: | --- | --- | --- | ---: | ---: | ---: | --- | --- |
| Net sales |  | $347,825 **​** | $263,223 | $84,602 |  | 32% | ​ | $917,518 | $744,515 | $173,003 |  | 23% |
| Gross profit | ​ | 104,568 ​ | 79,600 ​ | 24,968 | ​ | 31% | ​ | 289,933 ​ | 225,942 ​ | 63,991 | ​ | 28% |
| Selling, general and administrative expenses | ​ | 71,053 ​ | 59,676 ​ | 11,377 | ​ | 19% | ​ | 213,186 ​ | 191,043 ​ | 22,143 | ​ | 12% |
| Operating income | ​ | 33,515 ​ | 19,924 ​ | 13,591 | ​ | 68% | ​ | 76,747 ​ | 34,899 ​ | 41,848 | ​ | \* ​ |
| Interest expense, net | ​ | 9,355 ​ | 4,575 ​ | 4,780 | ​ | \* ​ | ​ | 25,992 ​ | 13,798 ​ | 12,194 | ​ | 88% |
| Foreign currency (gains) losses, net | ​ | (5,528) ​ | 2,427 ​ | (7,955) | ​ | \* ​ | ​ | 6,609 ​ | 16,593 ​ | (9,984) | ​ | (60)% |
| Income before income taxes | ​ | 29,688 ​ | 12,922 ​ | 16,766 | ​ | \* ​ | ​ | 44,146 ​ | 4,508 ​ | 39,638 | ​ | \* ​ |
| Provision for income taxes | ​ | 8,808 ​ | 4,517 ​ | 4,291 | ​ | 95% | ​ | 13,106 ​ | 2,844 ​ | 10,262 | ​ | \* ​ |
| Net income | ​ | $20,880 ​ | $8,405 ​ | $12,475 | ​ | \* ​ | ​ | $31,040 ​ | $1,664 ​ | $29,376 | ​ | \* ​ |
| ​ | ​ | ​ ​ ​ | ​ ​ ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ ​ | ​ ​ ​ | ​ ​ | ​ | ​ ​ |
| Net income per share | ​ | ​ | ​ ​ | ​ |  | ​ ​ | ​ | ​ | ​ ​ | ​ | ​ | ​ ​ |
| Basic | ​ | $0.52 ​ | $0.21 ​ | $0.31 | ​ | \* ​ | ​ | $0.77 ​ | $0.04 ​ | $0.73 | ​ | \* ​ |
| Diluted | ​ | $0.51 ​ | $0.21 ​ | $0.30 | ​ | \* ​ | ​ | $0.76 ​ | $0.04 ​ | $0.72 | ​ | \* ​ |
| ​ | ​ | ​ ​ ​ | ​ ​ ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ ​ | ​ ​ ​ | ​ ​ | ​ | ​ ​ |
| Weighted average number of shares outstanding | ​ | ​ | ​ ​ |  | ​ | ​ ​ | ​ | ​ | ​ ​ |  | ​ | ​ ​ |
| Basic | ​ | 40,520 ​ | 40,504 ​ |  | ​ | ​ ​ | ​ | 40,509 ​ | 40,504 ​ |  | ​ | ​ ​ |
| Diluted | ​ | ​ 40,709 ​ | ​ 40,520 ​ | ​ ​ | ​ | ​ ​ | ​ | ​ 40,669 ​ | ​ 40,509 ​ | ​ ​ | ​ | ​ ​ |
| ​ | ​ | ​ ​ ​ | ​ ​ ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ ​ | ​ ​ ​ | ​ ​ | ​ | ​ ​ |
| Ratio to net sales | ​ | ​ | ​ ​ |  | ​ | ​ ​ | ​ | ​ | ​ ​ |  | ​ | ​ ​ |
| Gross profit | ​ | 30.1% | 30.2% |  | ​ | ​ ​ | ​ | 31.6% | 30.3% |  | ​ | ​ ​ |
| Selling, general and administrative expenses | ​ | 20.4% | 22.7% |  | ​ | ​ ​ | ​ | 23.2% | 25.7% |  | ​ | ​ ​ |
| Operating income | ​ | 9.6% | 7.6% |  | ​ | ​ ​ | ​ | 8.4% | 4.7% |  | ​ | ​ ​ |
| Income before income taxes | ​ | 8.5% | 4.9% |  | ​ | ​ ​ | ​ | 4.8% | 0.6% |  | ​ | ​ ​ |
| Net income | ​ | 6.0% | 3.2% |  | ​ | ​ ​ | ​ | 3.4% | 0.2% | ​ | ​ | ​ ​ |
| Effective tax rate | ​ | 29.7% | 35.0% |  | ​ | ​ ​ | ​ | 29.7% | 63.1% |  | ​ | ​ ​ |

Certain amounts and percentages may reflect rounding adjustments.

\* Calculation not meaningful

### Net sales, Adjusted EBITDA and reconciliation of GAAP net income to Adjusted EBITDA

We report Net sales and Adjusted EBITDA by segment to understand the operating performance of each segment. This enables us to monitor changes in net sales, costs and other actionable operating metrics at the segment level. See “—General description of non-GAAP financial measures” for descriptions of EBITDA and Adjusted EBITDA.

Segment net sales and Adjusted EBITDA:

*(in thousands, except percentages)*

| ​ ​ For the Periods Ended March 31 Net sales | ​ ​ ​ | ​ ​ ​ Three Months 2025 | ​ ​ ​ 2024 | ​ ​ Change | ​ | ​ ​ ​ | ​ ​ ​ | ​ ​ ​ Nine Months 2025 | ​ ​ ​ 2024 | ​ ​ Change | ​ | ​ ​ ​ ​ ​ |
| --- | --- | ---: | ---: | ---: | --- | ---: | --- | ---: | ---: | ---: | --- | ---: |
| MFAs and other | ​ | $181,645 ​ | $108,216 ​ | $73,429 |  | 68% | ​ | $439,827 ​ | $304,261 ​ | $135,566 | ​ | 45% |
| Nutritional specialties | ​ | 43,350 ​ | 40,194 ​ | 3,156 |  | 8% | ​ | 131,908 ​ | 121,840 ​ | 10,068 | ​ | 8% |
| Vaccines | ​ | 33,382 ​ | 32,923 ​ | 459 |  | 1% | ​ | 98,583 ​ | 88,866 ​ | 9,717 | ​ | 11% |
| Animal Health | ​ | 258,377 ​ | 181,333 ​ | 77,044 |  | 42% | ​ | 670,318 ​ | 514,967 ​ | 155,351 | ​ | 30% |
| Mineral Nutrition | ​ | 66,774 ​ | 64,228 ​ | 2,546 |  | 4% | ​ | 189,086 ​ | 181,601 ​ | 7,485 | ​ | 4% |
| Performance Products | ​ | 22,674 ​ | 17,662 ​ | 5,012 |  | 28% | ​ | 58,114 ​ | 47,947 ​ | 10,167 | ​ | 21% |
| Total | ​ | $347,825 ​ | $263,223 ​ | $84,602 |  | 32% | ​ | $917,518 ​ | $744,515 ​ | $173,003 | ​ | 23% |
| ​ | ​ | ​ ​ ​ | ​ ​ ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ ​ | ​ ​ ​ | ​ ​ | ​ | ​ ​ |
| **Adjusted EBITDA** | ​ | ​ | ​ |  |  | ​ | ​ | ​ | ​ |  | ​ | ​ ​ |
| Animal Health | ​ | $63,123 ​ | $36,524 ​ | $26,599 |  | 73% | ​ | $161,684 ​ | $104,317 ​ | $57,367 | ​ | 55% |
| Mineral Nutrition | ​ | 5,762 ​ | 4,665 ​ | 1,097 |  | 24% | ​ | 15,226 ​ | 11,053 ​ | 4,173 | ​ | 38% |
| Performance Products | ​ | 3,336 ​ | 2,371 ​ | 965 |  | 41% | ​ | 7,513 ​ | 4,597 ​ | 2,916 | ​ | 63% |
| Corporate | ​ | (17,335) ​ | (13,856) ​ | (3,479) |  | (25)% | ​ | (50,706) ​ | (42,160) ​ | (8,546) | ​ | (20)% |
| Total | ​ | $54,886 ​ | $29,704 ​ | $25,182 |  | 85% | ​ | $133,717 ​ | $77,807 ​ | $55,910 | ​ | 72% |
| ​ | ​ | ​ ​ ​ | ​ ​ ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ ​ | ​ ​ ​ | ​ ​ | ​ | ​ ​ |
| Adjusted EBITDA as a percentage of segment net sales | ​ | ​ | ​ ​ |  |  | ​ | ​ | ​ | ​ ​ |  | ​ | ​ ​ |
| Animal Health | ​ | 24.4% | 20.1% |  |  | ​ | ​ | 24.1% | 20.3% |  | ​ | ​ ​ |
| Mineral Nutrition | ​ | 8.6% | 7.3% |  |  | ​ | ​ | 8.1% | 6.1% |  | ​ | ​ ​ |
| Performance Products | ​ | 14.7% | 13.4% |  |  | ​ | ​ | 12.9% | 9.6% |  | ​ | ​ ​ |
| Corporate (1) | ​ | (5.0)% | (5.3)% |  |  | ​ | ​ | (5.5)% | (5.7)% |  | ​ | ​ ​ |
| Total (1) | ​ | 15.8% | 11.3% |  |  | ​ | ​ | 14.6% | 10.5% |  | ​ | ​ ​ |

(1) Reflects ratio to total net sales

The table below sets forth a reconciliation of net income, as reported under GAAP, to Adjusted EBITDA:

*(in thousands, except percentages)*

| ​ ​ For the Periods Ended March 31 ​ | ​ ​ | ​ ​ Three Months 2025 | ​ | ​ ​ 2024 | ​ | ​ ​ Change | ​ | ​ ​ ​ | ​ ​ ​ | ​ ​ Nine Months 2025 | ​ | ​ ​ 2024 | ​ | ​ ​ Change | ​ | ​ ​ ​ ​ ​ |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net income | ​ | $20,880 | ​ | $8,405 | ​ | $12,475 | **​** | \* ​ | ​ | $31,040 | ​ | $1,664 | ​ | $29,376 |  | \* ​ |
| Interest expense, net | ​ | ​ 9,355 | ​ | ​ 4,575 | ​ | ​ 4,780 | ​ | \* ​ | ​ | ​ 25,992 | ​ | ​ 13,798 | ​ | ​ 12,194 | ​ | 88% |
| Provision for income taxes | ​ | ​ 8,808 | ​ | ​ 4,517 | ​ | ​ 4,291 | ​ | 95% | ​ | ​ 13,106 | ​ | ​ 2,844 | ​ | ​ 10,262 | ​ | \* ​ |
| Depreciation and amortization | ​ | ​ 12,616 | ​ | ​ 9,196 | ​ | ​ 3,420 | ​ | 37% | ​ | ​ 33,194 | ​ | ​ 26,977 | ​ | ​ 6,217 | ​ | 23% |
| EBITDA | ​ | ​ 51,659 | ​ | ​ 26,693 | ​ | ​ 24,966 | ​ | 94% | ​ | ​ 103,332 | ​ | ​ 45,283 | ​ | ​ 58,049 | ​ | \* ​ |
| Acquisition-related cost of goods sold | ​ | ​ 1,708 | ​ | ​ 211 | ​ | ​ 1,497 | ​ | \* ​ | ​ | ​ 3,342 | ​ | ​ 521 | ​ | ​ 2,821 | ​ | \* ​ |
| Acquisition-related other | ​ | ​ 636 | ​ | ​ 512 | ​ | ​ 124 | ​ | 24% | ​ | ​ 12,875 | ​ | ​ 512 | ​ | ​ 12,363 | ​ | \* ​ |
| Phibro Forward income growth initiatives - cost of goods sold (1) | ​ | ​ 3,798 | ​ | ​ — | ​ | ​ 3,798 | ​ | \* ​ | ​ | ​ 3,798 | ​ | ​ — | ​ | ​ 3,798 | ​ | \* ​ |
| Phibro Forward income growth initiatives - SG&A (1) | ​ | ​ 3,980 | ​ | ​ — | ​ | ​ 3,980 | ​ | \* ​ | ​ | ​ 6,026 | ​ | ​ — | ​ | ​ 6,026 | ​ | \* ​ |
| Stock-based compensation expense | ​ | ​ 179 | ​ | ​ 135 | ​ | ​ 44 |  | 33% | ​ | ​ 538 | ​ | ​ 296 | ​ | ​ 242 | ​ | 82% |
| Pension settlement cost |  | ​ — |  | ​ — |  | ​ — |  | \* ​ | ​ | ​ — |  | ​ 10,674 |  | ​ (10,674) | ​ | \* ​ |
| Brazil employment taxes | ​ | ​ — | ​ | ​ — | ​ | ​ — | ​ | \* ​ | ​ | ​ — | ​ | ​ 4,202 | ​ | ​ (4,202) | ​ | \* ​ |
| Insurance settlement gain | ​ | ​ (1,546) | ​ | ​ (274) | ​ | ​ (1,272) | ​ | \* ​ | ​ | ​ (2,803) | ​ | ​ (274) | ​ | ​ (2,529) | ​ | \* ​ |
| Foreign currency (gains) losses, net | ​ | ​ (5,528) |  | ​ 2,427 |  | ​ (7,955) |  | \* ​ | ​ | ​ 6,609 |  | ​ 16,593 |  | ​ (9,984) | ​ | (60)% |
| Adjusted EBITDA | ​ | $54,886 | ​ | $29,704 | ​ | $25,182 |  | 85% | ​ | $133,717 | ​ | $77,807 | ​ | $55,910 | ​ | 72% |

(1) Phibro Forward is a company-wide initiative focused on unlocking additional areas of revenue growth and cost savings. For the three and nine months ended March 31, 2025, this includes $5.3 million for non-cash asset write-offs, of which $3.8 million was recorded within cost of goods sold, and $1.5 million was recorded within selling, general, and administrative expenses, related to the closure of an immaterial business within the Animal Health segment.

Certain amounts may reflect rounding adjustments.

\* Calculation not meaningful

### Comparison of three months ended March 31, 2025 and 2024

### Net sales

Net sales of $347.8 million for the three months ended March 31, 2025 increased $84.6 million, or 32%, as compared to the three months ended March 31, 2024. Animal Health increased $77.0 million, while Mineral Nutrition and Performance Products increased $2.5 million and $5.0 million, respectively.

#### Animal Health

Net sales of $258.4 million for the three months ended March 31, 2025 increased $77.0 million, or 42%. Net sales of MFAs and other increased $73.4 million, or 68%, due to incremental revenues of $77.0 million from sales of products from the Zoetis MFA portfolio acquired on October 31, 2024, partially offset by lower poultry sales due in part to lower demand and the timing of sales.

Net sales of nutritional specialty products increased $3.2 million, or 8%, primarily due to increased poultry demand and higher sales of microbial and companion animal products.

Net sales of vaccines increased $0.5 million, or 1%, primarily due to continued growth of poultry products in Latin America, significantly offset by the timing of sales, impacted in part by import and other regulations in Asia.

#### Mineral Nutrition

Net sales of $66.8 million for the three months ended March 31, 2025 increased $2.5 million, or 4%, due to higher average selling prices for zinc and trace minerals.

#### Performance Products

Net sales of $22.7 million for the three months ended March 31, 2025 increased $5.0 million, or 28%, as a result of higher demand for the ingredients used in personal care products.

### Gross profit

Gross profit of $104.6 million for the three months ended March 31, 2025 increased $25.0 million, or 31%, as compared to the three months ended March 31, 2024. Gross margin decreased 10 basis points to 30.1% of net sales for the three months ended March 31, 2025, as compared to 30.2% for the three months ended March 31, 2024. The comparison to the prior year includes $3.8 million of current period inventory write-offs attributable to the closure of an immaterial business and a net increase of $1.5 million for acquisition-related cost of goods sold related to purchase accounting adjustments for acquisitions. Excluding these items, gross profit increased $30.3 million, or 38%, and gross margin increased 140 basis points to 31.6% of net sales due to increased sales, an increase in average selling prices, and the favorable impact of foreign currency exchange rates, partially offset by higher distribution costs.

Animal Health gross profit increased $27.8 million, primarily driven by higher sales volume, higher average selling prices, and the favorable impact of foreign currency exchange rates, partially offset by higher distribution costs. Mineral Nutrition gross profit increased $1.2 million, driven by higher average selling prices. Performance Products gross profit increased by $1.2 million, driven by increased sales volumes.

### Selling, general and administrative expenses

Selling, general and administrative expenses (“SG&A”) of $71.1 million for the three months ended March 31, 2025 increased $11.4 million, or 19%, as compared to the three months ended March 31, 2024. SG&A for the three months ended March 31, 2025 included $4.0 million of costs associated with Phibro Forward income growth initiatives, $0.6 million for acquisition-related costs, and $0.2 million of stock-based compensation expense, partially offset by $1.5 million related to an insurance settlement gain. SG&A for the three months ended March 31, 2024 included $0.5 million of acquisition-related costs and $0.1 million of stock-based compensation expense, partially offset by $0.3 million related to an insurance settlement gain. Excluding these items, SG&A increased $8.5 million.

Animal Health SG&A increased $5.1 million, primarily due to an increase in employee-related costs due in part to the incremental headcount added as part of the Acquisition. Mineral Nutrition and Performance Products SG&A was comparable to the prior year. Corporate costs increased by $3.2 million due to an increase in employee-related costs and professional fees.

### Interest expense, net

Interest expense, net of $9.4 million for the three months ended March 31, 2025 increased by $4.8 million, as compared to the three months ended March 31, 2024, due to the higher debt levels associated with the financing of the Acquisition.

### Foreign currency (gains) losses, net

Foreign currency gains for the three months ended March 31, 2025 were $5.5 million, as compared to $2.4 million of net losses for the three months ended March 31, 2024. Current period gains were driven by fluctuations in certain currencies related to the U.S. dollar, most prominently, in the Brazil Real and in the Euro. Prior year period losses were driven in large part by fluctuations in the Brazil Real.

### Provision for income taxes

The provision for income taxes was $8.8 million and $4.5 million for the three months ended March 31, 2025 and 2024, respectively. The effective income tax rates were 29.7% and 35.0% for the three months ended March 31, 2025 and 2024, respectively. The lower effective income tax rate for the three months ended March 31, 2025 is primarily due to higher pretax earnings and higher forecasted annual pretax earnings in the current period, which more significantly reduced the impact of certain items such as Global Intangible Low-Taxed Income (“GILTI”) when compared to the prior year. In addition, the effective tax rate for the three months ended March 31, 2024 includes the impact of changes in valuation allowances and other reserves, which more significantly increased the effective tax rate in the prior year than in the current year.

The provision for income taxes for the three months ended March 31, 2025 was increased by various items, including (i) different tax rates on exchange rate gains, (ii) changes in uncertain tax positions related to prior years and (iii) certain non-deductible write-offs in connection with the closure of an immaterial business included as part of the Phibro Forward initiatives. The provision for income taxes for the three months ended March 31, 2024 was increased by various items, including (i) different tax rates on exchange rate losses and (ii) changes in uncertain tax positions related to prior years. Excluding the impact of these items, the effective income tax rates were 25.7% and 30.8% for the three months ended March 31, 2025 and 2024, respectively.

### Net income

Net income of $20.9 million for the three months ended March 31, 2025 increased $12.5 million, as compared to net income of $8.4 million for the three months ended March 31, 2024. Operating income increased $13.6 million, driven by favorable gross profit, partially offset by higher SG&A. Gross profit increased primarily as a result of higher sales in the Animal Health segment, driven in part by incremental revenues associated with sales from the Zoetis MFA portfolio acquired on October 31, 2024. SG&A increased by $11.4 million, which included $4.0 million of costs associated with Phibro Forward income growth initiatives and higher employee-related costs due in part to the incremental headcount added as part of the Acquisition. Interest expense, net increased $4.8 million due to higher debt levels, due in part to the financing of the Acquisition. Foreign currency gains were $5.5 million, net increased by $8.0 million, as compared to $2.4 million of net losses for the three months ended March 31, 2024. Income tax expense increased by $4.3 million.

### Comparison of nine months ended March 31, 2025 and 2024

### Net sales

Net sales of $917.5 million for the nine months ended March 31, 2025 increased $173.0 million, or 23%, as compared to the nine months ended March 31, 2024. Animal Health sales increased $155.4 million. Mineral Nutrition and Performance Products sales increased $7.5 million and $10.2 million, respectively.

#### Animal Health

Net sales of $670.3 million for the nine months ended March 31, 2025 increased $155.4 million, or 30%. Net sales of MFAs and other increased $135.6 million, or 45%, due to incremental revenues of $113.7 million from sales of products from the Zoetis MFA portfolio acquired on October 31, 2024, increased demand for our MFAs in international regions and higher demand for processing aids used in the ethanol fermentation industry.

Net sales of nutritional specialty products increased $10.1 million, or 8%, primarily due to increased domestic dairy demand and higher sales of microbial and companion animal products.

Net sales of vaccines increased $9.7 million, or 11%, due primarily to continued growth of poultry products in Latin America and increased domestic demand for swine products, partially offset the impact of import and other regulations in Turkey and Asia.

#### Mineral Nutrition

Net sales of $189.1 million for the nine months ended March 31, 2025 increased $7.5 million, or 4%, due to an increase in demand for copper and trace minerals.

#### Performance Products

Net sales of $58.1 million for the nine months ended March 31, 2025 increased $10.2 million, or 21%, as a result of higher demand for the ingredients used in personal care products.

### Gross profit

Gross profit of $289.9 million for the nine months ended March 31, 2025 increased $64.0 million, or 28%, as compared to the nine months ended March 31, 2024. Gross margin increased 130 basis points to 31.6% of net sales for the nine months ended March 31, 2025, as compared to 30.3% for the nine months ended March 31, 2024. The comparison to the prior year includes $3.8 million of current period inventory write-offs attributable to the closure of an immaterial business and a net increase of $2.8 million for acquisition-related cost of goods sold related to purchase accounting adjustments for acquisitions. Excluding these items, gross profit increased $70.6 million, or 31%, and gross margin increased 200 basis points to 32.4% of net sales due to increased sales, an increase in average selling prices, and the favorable impact of foreign currency exchange rates, partially offset by higher distribution costs.

Animal Health gross profit increased $62.4 million, primarily driven by higher sales volume, higher average selling prices, and the favorable impact of foreign currency exchange rates, partially offset by higher distribution costs. Mineral Nutrition gross profit increased $4.6 million, driven by higher average selling prices. Performance Products gross profit increased $3.6 million, driven by increased sales volumes.

### Selling, general and administrative expenses

SG&A of $213.2 million for the nine months ended March 31, 2025 increased $22.1 million, or 12%, as compared to the nine months ended March 31, 2024. SG&A for the nine months ended March 31, 2025, included $12.9 million for acquisition-related costs, $6.0 million of costs associated with Phibro Forward income growth initiatives, and $0.5 million of stock-based compensation expense, partially offset by $2.8 million related to insurance settlement gains. SG&A for the nine months ended March 31, 2024, included a $10.7 million pension settlement costs, $4.2 million cost for an unfavorable litigation result related to Brazil employment taxes paid from January 2013 through December 2015, $0.5 million for acquisition-related costs, $0.3 million of stock-based compensation expense, partially offset by a $0.3 million insurance settlement gain. Excluding these items, SG&A increased $20.9 million.

Animal Health SG&A increased $12.3 million primarily due to an increase in employee-related costs due in part to incremental headcount added as part of the Acquisition and new product launches in Brazil. Mineral Nutrition and Performance Products SG&A was comparable to the prior year. Corporate expenses increased $8.3 million due to an increase in employee-related costs and professional fees.

### Interest expense, net

Interest expense, net of $26.0 million for the nine months ended March 31, 2025 increased $12.2 million, or 88%, as compared to the nine months ended March 31, 2024, due to the higher debt levels associated with the financing of the Acquisition and costs associated with the refinancing of the Company’s debt.

### Foreign currency (gains) losses, net

Foreign currency losses for the nine months ended March 31, 2025 were $6.6 million, as compared to net losses of $16.6 million for the nine months ended March 31, 2024. Current period losses were driven by fluctuations in certain currencies related to the U.S. dollar, most prominently, in the Brazil Real, the Argentine Peso, and the Mexican Peso. Prior year period losses were driven in large part by a major currency devaluation in Argentina.

### Provision for income taxes

The provision for income taxes was $13.1 million and $2.8 million for the nine months ended March 31, 2025 and 2024, respectively. The effective income tax rates were 29.7% and 63.1% for the nine months ended March 31, 2025 and 2024, respectively. The lower effective income tax rate for the nine months ended March 31, 2025 is primarily due to higher pretax earnings and higher forecasted annual pretax earnings in the current period, which more significantly reduced the impact of certain items such as GILTI when compared to the prior year. In addition, the effective tax rate for the nine months ended March 31, 2024 includes the impact of changes in valuation allowances and other reserves, which more significantly increased the effective tax rate in the prior year than in the current year.

The provision for income taxes for the nine months ended March 31, 2025 was increased by various items, including (i) different tax rates on exchange rate losses, (ii) changes in uncertain tax positions related to prior years and (iii) certain non-deductible write-offs in connection with the closure of an immaterial business included as part of the Phibro Forward initiatives. The provision for income taxes for the nine months ended March 31, 2024 was changed by various items, including (i) a tax benefit from a foreign tax credit related to the prior year based on Internal Revenue Service guidance provided subsequent to our fiscal year-end, (ii) a tax benefit related to the release of certain valuation allowances on non-U.S. companies, (iii) expenses from changes in uncertain tax positions related to prior years, and (iv) different tax rates on exchange rate losses. Excluding the impact of these items, the effective income tax rate was 25.3% and 28.6% for the nine months ended March 31, 2025 and 2024, respectively.

### Net income

Net income was $31.0 million for the nine months ended March 31, 2025, as compared to net income of $1.7 million for the nine months ended March 31, 2024. Operating income increased $41.8 million driven by higher gross profit, partially offset by higher SG&A of $22.1 million, which included a net increase of $12.4 million in acquisition-related costs and $6.0 million of costs associated with Phibro Forward income growth initiatives. Interest expense, net increased $12.2 million due to higher debt levels and the associated with the refinancing of the Company’s debt. Foreign currency losses, net decreased by $10.0 million. Income tax expense increased by $10.3 million.

### Adjusted net income and adjusted diluted earnings per share

We report adjusted net income and adjusted diluted earnings per share to portray the results of our operations prior to considering certain income statement elements. See “—General description of non-GAAP financial measures” for more information.

A reconciliation of net income, as reported under GAAP, to adjusted net income, is as follows:

*(in thousands, except per share amounts and percentages)*

| ​ ​ For the Periods Ended March 31 ​ Reconciliation of GAAP Net Income to Adjusted Net Income | ​ ​ ​ ​ | ​ ​ Three Months 2025 ​ | ​ ​ | ​ ​ 2024 | ​ ​ | ​ ​ Change | ​ | ​ ​ ​ | ​ ​ ​ ​ | ​ ​ Nine Months 2025 | ​ ​ | ​ ​ 2024 | ​ ​ | ​ ​ Change | ​ | ​ ​ ​ |
| --- | --- | ---: | --- | ---: | --- | ---: | --- | --- | --- | ---: | --- | ---: | --- | ---: | --- | ---: |
| Net income | ​ | $20,880 | ​ | $8,405 | ​ | $12,475 |  | \* ​ | ​ | $31,040 | ​ | $1,664 | ​ | $29,376 |  | \* ​ |
| Adjustments | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| Acquisition-related items, net of income tax (1) | ​ | 3,033 | ​ | 2,340 | ​ | 693 |  | 30% | ​ | 16,717 | ​ | ​ 6,208 | ​ | 10,509 |  | \* ​ |
| Certain items, net of income tax (1) | ​ | ​ 5,650 | ​ | ​ (90) | ​ | ​ 5,740 |  | \* ​ | ​ | ​ 8,036 | ​ | ​ 10,850 | ​ | ​ (2,814) |  | (26)% |
| Foreign currency (gains) losses, net of income tax (1) | ​ | (4,037) | ​ | 1,416 | ​ | (5,453) |  | \* ​ | ​ | 5,233 | ​ | 13,670 | ​ | (8,437) |  | (62)% |
| Certain income tax items (1) | ​ | 190 | ​ | 626 | ​ | (436) |  | (70)% | ​ | 691 | ​ | (695) | ​ | 1,386 |  | \* ​ |
| Total adjustments, net of income tax | ​ | ​ 4,836 | ​ | ​ 4,292 | ​ | ​ 544 | ​ | 13% | ​ | ​ 30,677 | ​ | ​ 30,033 | ​ | ​ 644 | ​ | 2% |
| Adjusted net income | ​ | $25,716 | ​ | $12,697 | ​ | $13,019 |  | \* ​ | ​ | $61,717 | ​ | $31,697 | ​ | $30,020 |  | 95% |

(1) See table titled “Items Excluded from Adjusted Net Income” below for further details.

A reconciliation of reported diluted earnings per share, as reported under GAAP, to non-GAAP adjusted diluted EPS is:

*(in thousands, except per share amounts and percentages)*

| ​ ​ For the Periods Ended March 31 ​ Reconciliation of GAAP diluted EPS to Adjusted diluted EPS | ​ ​ ​ | ​ ​ Three Months 2025 ​ ​ ​ | ​ ​ | ​ ​ 2024 ​ ​ | ​ ​ | ​ ​ Change ​ ​ | ​ ​ | ​ ​ ​ ​ ​ | ​ ​ ​ ​ | ​ ​ Nine Months 2025 ​ ​ | ​ ​ | ​ ​ 2024 ​ ​ | ​ ​ | ​ ​ Change ​ ​ | ​ ​ | ​ ​ ​ ​ ​ |
| --- | --- | ---: | --- | ---: | --- | ---: | --- | --- | --- | ---: | --- | ---: | --- | ---: | --- | ---: |
| GAAP EPS, diluted | ​ | $0.51 | ​ | $0.21 | ​ | $0.30 |  | \* ​ | ​ | $0.76 | ​ | $0.04 | ​ | $0.72 |  | \* ​ |
| Adjustments | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| Acquisition-related items, net of income tax | ​ | 0.07 | ​ | 0.06 | ​ | 0.01 |  | 17% | ​ | 0.41 | ​ | 0.15 | ​ | 0.26 |  | \* ​ |
| Certain items, net of income tax | ​ | 0.14 | ​ | - | ​ | 0.14 |  | \* ​ | ​ | 0.20 | ​ | 0.27 | ​ | (0.07) |  | (25)% |
| Foreign currency (gains) losses, net of income tax | ​ | (0.10) | ​ | 0.03 | ​ | (0.13) |  | \* ​ | ​ | 0.13 | ​ | 0.34 | ​ | (0.21) |  | (61)% |
| Certain income tax items | ​ | - | ​ | 0.02 | ​ | (0.02) |  | \* ​ | ​ | 0.02 | ​ | (0.02) | ​ | 0.04 |  | \* ​ |
| Adjustments EPS, diluted | ​ | ​ 0.11 | ​ | ​ 0.11 | ​ | ​ 0.00 | ​ | \* ​ | ​ | ​ 0.76 | ​ | ​ 0.74 | ​ | ​ 0.02 | ​ | 3% |
| Adjusted EPS, diluted | ​ | $0.63 | ​ | $0.31 | ​ | $0.32 |  | \* ​ | ​ | $1.52 | ​ | $0.78 | ​ | $0.74 |  | 95% |

Items excluded from adjusted net income consisted of:

*(in thousands)*

| ​ ​ For the Periods Ended March 31 ​ Items Excluded from Adjusted Net Income Acquisition-related items | ​ ​ ​ ​ ​ ​ | ​ ​ Three Months 2025 ​ ​ ​ ​ | ​ ​ ​ | ​ ​ 2024 ​ ​ ​ ​ | ​ ​ ​ ​ ​ | ​ ​ Nine Months 2025 ​ ​ ​ ​ | ​ ​ ​ | ​ ​ 2024 ​ ​ ​ ​ |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Acquisition-related cost of goods sold | **​** | $1,708 | **​** | $211 | ​ | $3,342 | **​** | $521 |
| Acquisition-related intangible amortization in cost of goods sold | ​ | ​ 1,132 | ​ | ​ 1,671 | ​ | ​ 4,361 | ​ | ​ 5,014 |
| Acquisition-related intangible amortization in SG&A | ​ | ​ 587 | ​ | 756 | ​ | ​ 1,785 | ​ | 2,325 |
| Acquisition-related transaction costs in SG&A | ​ | ​ 636 | ​ | 512 | ​ | ​ 12,875 | ​ | 512 |
| Acquisition-related items - income taxes | ​ | ​ (1,030) | ​ | ​ (810) | ​ | ​ (5,646) | ​ | ​ (2,164) |
| **Total acquisition-related items, net of income taxes** | ​ | 3,033 | ​ | 2,340 | ​ | 16,717 | ​ | 6,208 |
| ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| **Certain items** | **​** | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| Pension settlement cost | ​ | ​ — | ​ | — | ​ | ​ — | ​ | 10,674 |
| Stock-based compensation expense | ​ | ​ 179 | ​ | 135 | ​ | ​ 538 | ​ | 296 |
| Phibro Forward income growth initiatives - cost of goods sold | ​ | ​ 3,798 | ​ | — | ​ | ​ 3,798 | ​ | — |
| Phibro Forward income growth initiatives - SG&A | **​** | ​ 3,980 | ​ | ​ — | ​ | ​ 6,026 | ​ | ​ — |
| Insurance settlement gain | ​ | ​ (1,546) | ​ | ​ (274) | ​ | ​ (2,803) | ​ | ​ (274) |
| Brazil employment taxes | ​ | ​ — | ​ | ​ — | ​ | ​ — | ​ | ​ 4,202 |
| Refinancing expense | **​** | ​ — | ​ | ​ — | ​ | ​ 1,960 | ​ | ​ — |
| Certain items - income taxes | ​ | ​ (761) | ​ | ​ 49 | ​ | ​ (1,483) | ​ | ​ (4,048) |
| **Total certain items, net of income taxes** | ​ | ​ 5,650 | ​ | ​ (90) | ​ | ​ 8,036 | ​ | ​ 10,850 |
| ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| **Foreign currency (gains) losses, net** | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| Foreign currency (gains) losses, net | **​** | ​ (5,528) | ​ | 2,427 | ​ | ​ 6,609 | ​ | 16,593 |
| Foreign currency (gains) losses, net - income taxes | **​** | ​ 1,491 | ​ | ​ (1,011) | ​ | ​ (1,376) | ​ | ​ (2,923) |
| **Total foreign currency losses, net, net of income taxes** | **​** | ​ (4,037) | ​ | ​ 1,416 | ​ | ​ 5,233 | ​ | ​ 13,670 |
| ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| **Certain income tax items** | **​** | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| Foreign tax credit regulations | ​ | ​ — | ​ | ​ — | ​ | ​ — | ​ | ​ (1,223) |
| Changes in uncertain tax positions and certain other items | **​** | ​ 190 | ​ | ​ 627 | ​ | ​ 691 | ​ | ​ 528 |
| **Total certain income tax items** | **​** | ​ 190 | ​ | ​ 627 | ​ | ​ 691 | ​ | ​ (695) |
| **​** | **​** | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| **Total adjustments, net of income taxes** | **​** | $4,836 | ​ | $4,293 | ​ | $30,677 | ​ | $30,033 |

### Analysis of financial condition, liquidity and capital resources

Net (decrease) increase in cash and cash equivalents was as follows:

*(in thousands)*

| ​ ​ For the Periods Ended March 31 ​ Cash provided (used) by: | ​ ​ ​ | ​ ​ Nine Months 2025 ​ ​ | ​ ​ | ​ ​ 2024 ​ ​ | ​ ​ | ​ ​ Change ​ ​ |
| --- | --- | ---: | --- | ---: | --- | ---: |
| Operating activities | ​ | $58,852 | ​ | $59,165 | ​ | $(313) |
| Investing activities | ​ | (281,654) | ​ | (39,083) | ​ | (242,571) |
| Financing activities | ​ | 214,900 | ​ | (8,555) | ​ | 223,455 |
| Effect of exchange-rate changes on cash and cash equivalents | ​ | (2,357) | ​ | (2,583) | ​ | 226 |
| Net (decrease) increase in cash and cash equivalents | ​ | $(10,259) | ​ | $8,944 | ​ | $(19,203) |

Certain amounts may reflect rounding adjustments.

#### Operating activities

Operating activities provided $58.9 million of net cash for the nine months ended March 31, 2025. Cash provided by net income, adjusted for the non-cash items, including depreciation and amortization, was $66.2 million. Cash used in the ordinary course of business from changes in operating assets and liabilities, net of the impact of the net assets acquired from the Acquisition, was $7.3 million. Accounts receivable used $29.3 million of cash due to higher sales. Inventories used $38.1 million of cash due to increased quantities on hand due to timing of inventory purchases and forecasted future demand. Accounts payable provided $42.9 million of cash due to timing of purchases and payments. Accrued expenses and other liabilities provided cash of $21.0 million, primarily due to timing of incurrence.

#### Investing activities

Investing activities used $281.7 million of net cash for the nine months ended March 31, 2025, which includes the purchase price paid for the Acquisition of $291.9 million, net of cash acquired. Capital expenditures totaled $25.2 million, as we continue to invest in expanding production capacity and productivity improvements. Purchases of our short-term investments used $10.0 million of cash, and maturities of our short-term investments provided $44.0 million in cash.

#### Financing activities

Financing activities provided $214.9 million of net cash for the nine months ended March 31, 2025 and reflect the impact of the refinancing of our debt portfolio in July 2024 and the financing of the Acquisition. Proceeds of $300.0 million from the refinancing, as well as revolving credit facility borrowings were used to pay the remaining principal balances of the outstanding debt of $313.1 million, and we used the proceeds $350.0 million in term loan borrowings to finance the purchase price of the Acquisition. Net revolver payments on our credit facilities used $84.0 million in cash. We paid $7.8 million in scheduled quarterly principal payments on long-term debt during the nine months ended March 31, 2025. We also paid $10.4 million in debt issuance costs related to the refinancing and $14.6 million in dividends to holders of our Class A common stock and Class B common stock.

#### Liquidity and capital resources

We believe our cash on hand, operating cash flows and financing arrangements, including the availability of borrowings under the 2024 Credit Facility, will be sufficient to support our ongoing cash needs. We have considered the current and potential future effects of the macroeconomic market conditions in the financial markets. At this time, we expect adequate liquidity for at least the next twelve months. We can provide no assurance that our liquidity and capital resources will be adequate for future funding requirements. We believe we will be able to comply with the terms of the covenants under the 2024 Credit Facilities based on our operating plan. In the event of adverse operating results and/or violation of covenants under the facilities, there can be no assurance we would be able to obtain waivers or amendments. Other risks to our meeting future funding requirements include global economic conditions and macroeconomic, business and financial disruptions that could arise, including ongoing conflicts between Russia and Ukraine and hostilities in the Middle East. There can be no assurance that a challenging economic environment or an economic downturn would not affect our liquidity or ability to obtain future financing or fund operations or investment opportunities. In addition, our debt covenants may restrict our ability to invest.

Certain relevant measures of our liquidity and capital resources follow:

*(in thousands, except ratios)*

| ​ ​ As of ​ | ​ ​ | ​ ​ March 31, 2025 | ​ | ​ ​ June 30, 2024 |
| --- | --- | ---: | --- | ---: |
| Cash and cash equivalents and short-term investments | ​ | $70,354 | ​ | $114,613 |
| Working capital | ​ | 455,433 | ​ | 312,031 |
| Ratio of current assets to current liabilities | ​ | 2.82:1 | ​ | 2.79:1 |

We define working capital as total current assets (excluding cash and cash equivalents and short-term investments) less total current liabilities (excluding current portion of long-term debt). We calculate the ratio of current assets to current liabilities based on this definition.

As of March 31, 2025, we had $92.0 million in outstanding borrowings under the 2024 Revolver and outstanding letters of credit and other commitments of $2.4 million, leaving $215.6 million available for further borrowings and letters of credit, subject to restrictions in our 2024 Credit Facilities

We currently intend to pay quarterly dividends on our Class A common stock and Class B common stock, subject to approval from the Board of Directors. On May 6, 2025, our Board of Directors declared a cash dividend of $0.12 per share on Class A common stock and Class B common stock, payable on June 25, 2025. Our future ability to pay dividends will depend upon our results of operations, financial condition, capital requirements, our ability to obtain funds from our subsidiaries and other factors that our Board of Directors deems relevant. Additionally, the terms of our current and any future agreements governing our indebtedness could limit our ability to pay dividends or make other distributions.

As of March 31, 2025, our cash and cash equivalents and short-term investments included $68.4 million held by our international subsidiaries. There are no restrictions on cash distributions to PAHC from our international subsidiaries. Distributions may be subject to taxation by U.S. or non-U.S. taxing authorities.

### Contractual obligations

As of March 31, 2025, there were no material changes in payments due under contractual obligations from those disclosed in the Annual Report.

### Off-balance sheet arrangements

We do not currently use off-balance sheet arrangements for the purpose of credit enhancement, hedging transactions, investment or other financial purposes.

In the ordinary course of business, we may indemnify our counterparties against certain liabilities that may arise. These indemnifications typically pertain to environmental matters. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we would be required to reimburse the loss. These indemnifications generally are subject to certain restrictions and limitations.

### General description of non-GAAP financial measures

### Adjusted EBITDA

Adjusted EBITDA is an alternative view of performance used by management as our primary operating measure, and we believe that investors’ understanding of our performance is enhanced by disclosing this performance measure. We report Adjusted EBITDA to reflect the results of our operations prior to considering certain income statement elements and to make financial and operating decisions. We calculate EBITDA as net income plus (i) interest expense, net, (ii) provision for income taxes or less benefit for income taxes and (iii) depreciation and amortization. We calculate Adjusted EBITDA as EBITDA plus (a) other expense or less other income, as separately reported on our consolidated statements of operations, including foreign currency (gains) losses, net and (b) certain items that we consider to be unusual, non-operational or non-recurring. The Adjusted EBITDA measure is not, and should not be viewed as, a substitute for GAAP reported net income and should not be viewed as a measure of liquidity.

The Adjusted EBITDA measure is an important internal measurement for us. We measure our overall performance on this basis in conjunction with other performance metrics. The following are examples of how our Adjusted EBITDA measure is utilized:

- senior management receives a monthly analysis of our operating results that is prepared on an Adjusted EBITDA basis;
- our annual budgets are prepared on an Adjusted EBITDA basis; and
- other goal-setting and performance measurements are prepared on an Adjusted EBITDA basis.

Despite the importance of this measure to management in goal setting and performance measurement, Adjusted EBITDA is a non-GAAP financial measure that has no standardized meaning prescribed by GAAP and, therefore, has limits in its usefulness to investors. Because of its non-standardized definition, Adjusted EBITDA, unlike GAAP net income, may not be comparable to the calculation of similar measures of other companies. Adjusted EBITDA is presented to permit investors to more fully understand how management assesses performance.

We also recognize that, as an internal measure of performance, the Adjusted EBITDA measure has limitations, and we do not restrict our performance management process solely to this metric. A limitation of the Adjusted EBITDA measure is that it provides a view of our operations without including all events during a period, such as the depreciation of property, plant and equipment or amortization of acquired intangibles, and does not provide a comparable view of our performance to other companies.

### Adjusted net income and adjusted diluted earnings per share

Adjusted net income and adjusted diluted earnings per share represent alternative views of performance, and we believe investors’ understanding of our performance is enhanced by disclosing these performance measures. We report adjusted net income and adjusted diluted earnings per share to portray the results of our operations prior to considering certain income statement elements. We calculate adjusted net income as net income plus (i) acquisition-related intangible amortization and other acquisition-related items, (ii) certain items we consider to be unusual, non-operational or non-recurring, (iii) stock-based compensation expense, (iv) foreign currency (gains) losses, as separately reported on our consolidated statements of operations, and (v) the income tax effect of pre-tax income adjustments and certain income tax items. Adjusted diluted earnings per share is calculated using the adjusted net income divided by the diluted weighted average number of shares. The adjusted net income and adjusted diluted earnings per share measures are not, and should not be viewed as, a substitute for GAAP reported net income.

Adjusted net income and adjusted diluted earnings per share are non-GAAP financial measures that have no standardized meaning prescribed by GAAP and, therefore, have limits in their usefulness to investors. Because of its non-standardized definition, adjusted net income and adjusted diluted earnings per share, unlike GAAP net income, may not be comparable to the calculation of similar measures of other companies. Adjusted net income and adjusted diluted earnings per share are presented to permit investors to more fully understand how management assesses performance.

### Certain significant items

Adjusted EBITDA, adjusted net income and adjusted diluted earnings per share are calculated prior to considering acquisition-related items and certain other items, as detailed in the table titled “Items Excluded from Adjusted Net Income” above. We evaluate such items on an individual basis. Such evaluation considers both the quantitative and the qualitative aspect of their unusual or non-operational or non-recurring nature. Unusual, in this context, may represent items that are not part of our ongoing business; items that, either as a result of their nature or size, we would not expect to occur as part of our normal business on a regular basis.

We consider acquisition-related activities and business restructuring costs related to productivity and cost saving initiatives to be unusual items that we do not expect to occur as part of our normal business on a regular basis. We consider foreign currency gains and losses to be non-operational because they arise principally from intercompany transactions and are largely non-cash in nature.

### New accounting standards

For discussion of new accounting standards, see “Notes to Consolidated Financial Statements—Summary of Significant Accounting Policies and New Accounting Standards.”

### Critical Accounting Policies

Our significant accounting policies, which include management’s best estimates and judgments, are included in Note 2 to the consolidated financial statements for the year ended June 30, 2024, included in our Annual Report on Form 10-K filed with the Securities Exchange Commission on August 28, 2024. There have been no significant changes in our critical accounting estimates since June 30, 2024.

### Forward-Looking Statements

This Quarterly Report on Form 10-Q contains forward-looking statements that are subject to risks and uncertainties. All statements other than statements of historical or current fact included in this report are forward-looking statements. Forward-looking statements discuss our current expectations and projections relating to our financial condition, results of operations, plans, objectives, future performance and business. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as “aim,” “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “outlook,” “potential,” “project,” “projection,” “plan,” “intend,” “seek,” “may,” “could,” “would,” “will,” “should,” “can,” “can have,” “likely,” the negatives thereof and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events. For example, all statements we make relating to our estimated and projected earnings, revenues, costs, expenditures, cash flows, growth rates and financial results, our plans and objectives for future operations, growth or initiatives, strategies, or the expected outcome or impact of pending or threatened litigation are forward-looking statements. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that we expected. Examples of such risks and uncertainties include:

- outbreaks of animal diseases could significantly reduce demand for our products or availability of raw materials;
- perceived adverse effects on human health linked to the consumption of food derived from animals that utilize our products could cause a decline in the sales of those products;
- restrictions on the use of antibacterials in food-producing animals may become more prevalent;
- the potential FDA withdrawal of approval of our Mecadox® (carbadox) product;
- a material portion of our sales and gross profits are generated by antibacterials and other related products;
- competition in each of our markets from a number of large and small companies, some of which have greater financial, research and development (“R&D”), production and other resources than we have;
- our business may be negatively affected by weather conditions and the availability of natural resources;
- the negative effects of a pandemic, epidemic, or outbreak of an infectious disease in humans, such as COVID-19; on our business, financial results, manufacturing facilities and supply chain, as well as our customers, protein processors and markets;
- climate change could have a material adverse impact on our operations and our customers’ businesses;
- actions of regulatory bodies, including obtaining approvals related to the testing, manufacturing and marketing of certain of our products;
- the continuing trend toward consolidation of certain customer groups as well as the emergence of large buying groups;
- our ability to control costs and expenses;
- any unforeseen material loss or casualty;
- misuse or extra-label use of our products;
- exposure relating to rising costs and reduced customer income;
- heightened competition, including those from generics and those deriving from advances in veterinary medical practices and animal health technologies;
- unanticipated safety or efficacy concerns;
- our dependence on suppliers having current regulatory approvals;
- our raw materials are subject to price fluctuations and their availability can be limited;
- natural and man-made disasters, including but not limited to fire, snow and ice storms, flood, hail, hurricanes and earthquakes;
- business interruption from political and social instability, including crime, civil disturbance, terrorist activities, outbreaks of disease and pandemics and armed conflicts, such as potential hostilities in the Middle East and ongoing armed conflicts between Russia and Ukraine;
- terrorist attacks, particularly attacks on or within markets in which we operate, including the terrorist attack on Israel by Hamas militants and the Hezbollah terrorist organization;
- risks related to changes in tax rates and exposure;
- our ability to successfully implement our strategic initiatives;
- our reliance on the continued operation of our manufacturing facilities and application of our intellectual property;
- adverse U.S. and international economic market conditions, including currency fluctuations;
- failure of our product approval, R&D, acquisition and licensing efforts to generate new products;
- the risks of product liability claims, legal proceedings and general litigation expenses;
- the impact of current and future laws and regulatory changes, including risks related to the protection of our customers’ privacy and risks related to environmental, health and safety laws and regulations;
- modification of foreign trade policy, including without limitation, any new or increased tariffs or retaliatory measures in response to such modification, may negatively impact our profitability and may harm our food animal product customers;
- our ability to successfully integrate acquired businesses, including the medicated feed additive product portfolio, certain water-soluble products and related assets, which we have agreed to acquire from Zoetis Inc.;
- our dependence on our Israeli and Brazilian operations;
- impact of increased or decreased inventory levels at our direct customers or channel distributors;
- our substantial level of indebtedness and related debt-service obligations;
- restrictions imposed by covenants in our debt agreements;
- the risk of breaches of data security and cybersecurity attacks;
- our dependence on sophisticated information technology and infrastructure, including the risks associated with the use of artificial intelligence in our business;
- the risk of work stoppages; and
- other factors as described in “Risk Factors” in Item 1A of our Annual Report.

While we believe that our assumptions are reasonable, we caution that it is very difficult to predict the impact of known factors, and it is impossible for us to anticipate all factors that could affect our actual results. Important factors that could cause actual results to differ materially from our expectations, or cautionary statements, are disclosed under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” All forward-looking statements are expressly qualified in their entirety by these cautionary statements. You should evaluate all forward-looking statements made in this report in the context of these risks and uncertainties.

We caution you that the important factors referenced above may not contain all of the factors that are important to you. In addition, we cannot assure you that we will realize the results or developments we expect or anticipate or, even if substantially realized, that they will result in the consequences we anticipate or affect us or our operations in the way we expect. The forward-looking statements included in this report are made only as of the date hereof. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law. If we do update one or more forward-looking statements, no inference should be made that we will make additional updates with respect to those or other forward-looking statements.

## Market risk

As filed, 1,306 characters.

In the normal course of operations, we are exposed to market risks arising from adverse changes in interest rates, foreign currency exchange rates and commodity prices. As a result, future earnings, cash flows and fair values of assets and liabilities are subject to uncertainty. We use, from time to time, foreign currency contracts and interest rate swaps as a means of hedging exposure to foreign currency risks and fluctuating interest rates, respectively. We do not utilize derivative instruments for trading or speculative purposes. We do not hedge our exposure to market risks in a manner that eliminates the effects of changing market conditions on earnings, cash flows and fair values. We monitor the financial stability and credit standing of our major counterparties.

For financial market risks related to changes in interest rates and foreign currency exchange rates, reference is made to the “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Qualitative and Quantitative Disclosures about Market Risk” section in the Annual Report and to the notes to the consolidated financial statements included therein. As of the date of this report, there were no material changes in the Company’s financial market risks from the risks disclosed in the Annual Report.

## Controls and procedures

As filed, 873 characters.

### Evaluation of Disclosure Controls and Procedures

An evaluation was carried out under the supervision and with the participation of the Company’s management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended). Based upon that evaluation as of March 31, 2025, our Chief Executive Officer and Chief Financial Officer each concluded that, as of the end of such period, our disclosure controls and procedures were effective.

### Changes in Internal Control over Financial Reporting

There were no changes that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting during the quarter ended March 31, 2025.

## Risk factors

As filed, 380 characters.

In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in “Risk Factors” in Item 1A of our Annual Report, which could materially affect our business, financial condition or future results.

There were no material changes in the Company’s risk factors from the risks disclosed in the Annual Report.

Filed May 7, 2025.
Source: SEC EDGAR, the filing index for accession 0001558370-25-006746. Last ingested by Listed: Nov 4, 2026, 17:49 ET. No prices; not investment advice.